Unique Molecular CT Takes Centre Stage at Queen Alexandra Hospital in Portsmouth | Siemens Healthcare
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Siemens Healthcare Unique Molecular CT Takes Centre Stage at Queen Alexandra Hospital in Portsmouth

Unique Molecular CT Takes Centre Stage at Queen Alexandra Hospital in Portsmouth

Company News - Siemens Healthcare

Two systems with the footprint of one commences research trials

The state-of-the-art Queen Alexandra Hospital, part of Portsmouth Hospitals NHS Trust, which opened last year, has recently begun using an advanced hybrid PET.CT from Siemens Healthcare.  The BiographT mCT is a new concept scanner that combines the first advanced HD.PET platform and the world's first Adaptive Spiral CT to create a next generation dual modality device for a new level of integrated imaging.

The Biograph mCT is currently being used by the Nuclear Medicine department for a series of research trials where its exceptional image quality and low patient doses are proving highly beneficial.  Patient imaging, including scanning cancer patients for treatment planning, staging and management, will commence in due time.

PETNET Solutions, a division of Siemens plc, supplies the Trust with its MetaTrace FDG biomarker for use with the Biograph mCT.  In order to support the Trust's research projects it is expected that some novel biomarkers will be supplied in the near future.

"The ultraHD.PET technology gives us distortion free images and uniform resolution across the entire field of view  and improved signal-to-noise ratio," said Dr. Michael Masoomi, Consultant Clinical Scientist, Head of Nuclear Medicine at Queen Alexandra Hospital.  "We also have the option to use the system as a standard CT later down the line when the need requires.

This provides a better return on investment and will enable us to maximise the benefits of two systems with the footprint of one.  Reliable and consistent delivery of biomarkers from PETNET Solutions has been another advantage since the installation."

"Queen Alexandra Hospital offers patient facilities that are amongst the best in Europe," said Lawrence Foulsham, Product Manager for Molecular Imaging and Oncology at Siemens Healthcare.  "The Biograph mCT is a true next generation system with the ability to adapt to virtually all patients and clinical needs plus perform as a standalone CT if required.  This helps to save on the time, space and costs associated with multiple installations."

Source: Siemens Healthcare